|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1305 Corporate Center Drive |
Address2 |
|
City | Eagan |
State | MN |
Zip Code | 55121 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Eagan |
State | MN |
Zip Code | 55121 |
Country | USA |
|
5. Senate ID# 400339576-12
|
||||||||
|
6. House ID# 403630000
|
TYPE OF REPORT | 8. Year | 2017 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: David Root |
Date | 4/19/2017 4:27:39 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Generic drug user fee act - provisions to ensure greater market competition for generics. Biosimilar drug user fee act - ensuring greater competition in the biosimilar market. S.469/H.R.1245: Affordable and Safe Prescription Drug Importation Act. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act - issues relating to ensuring a competitive drug marketplace. S.778:Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Cantor-Weinberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
HR 749: Lower Drug Costs Through Competition Act - increasing generic competition. Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. Generic drug user fee act - provisions to ensure greater market competition for generics. Biosimilar drug user fee act - ensuring greater competition in the biosimilar market. HR 1121: Preexisting Conditions Protect Act of 2017 - issues relating to market stability in exchanges. S. 191: Patient Freedom Act of 2017 - issues relating to market stability in exchanges. S. 469/H.R. 1245: Affordable and Safe Prescription Drug Importation Act. H.R. 1316: The Prescription Drug Price Transparency Act - issues relating to ensuring continued use of MAC pricing. S. 771/H.R. 1776: Improving Access to Affordable Prescription Drugs Act - issues relating to ensuring a competitive drug marketplace. H.R. 1628: The American Health Care Act of 2017 - issues related to market stabilization. S.778: Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Cantor-Weinberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act - restrictions on payor quallity programs in Medicare Part D. Draft bill to amend title XVIII of the Social Security Act to provide for greater access to drug cost information for Medicare beneficiaries by preventing cash price disclosure restrictions under Medicare prescription drug plan contracts with pharmacies - issues related to noninterference in Medicare Part D. Counter efforts to elimination of the Medicare Part D non-interference clause. H.R. 1316: The Prescription Drug Price Transparency Act - issues relating to ensuring continued use of MAC pricing. S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act - Issues relating to Medicare Part D cash price disclosure. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act - issues relating to ensuring a competitive drug marketplace. Draft bill to amend part A of title XVIII of the Social Security Act to provide greater access to information regarding the items and services furnished to the individual under parts A and B of the Medicare program and greater context regarding the medication regimen of the individual - issues relating to use of Medicare data.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Cantor-Weinberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
S. 778: Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Cantor-Weinberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
ALC |
MMM |
PHA |
HCR |
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |